

Stacy E Croteau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/532420/publications.pdf>

Version: 2024-02-01

61
papers

1,213
citations

471371

17
h-index

395590

33
g-index

62
all docs

62
docs citations

62
times ranked

1343
citing authors

#	ARTICLE	IF	CITATIONS
1	Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 Referrals. <i>Journal of Pediatrics</i> , 2013, 162, 142-147.	0.9	314
2	Kaposiform Lymphangiomas: A Distinct Aggressive Lymphatic Anomaly. <i>Journal of Pediatrics</i> , 2014, 164, 383-388.	0.9	127
3	2017 Clinical trials update: Innovations in hemophilia therapy. <i>American Journal of Hematology</i> , 2016, 91, 1252-1260.	2.0	82
4	Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. <i>Frontiers in Pediatrics</i> , 2017, 5, 68.	0.9	53
5	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	1.0	50
6	A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds. <i>Blood</i> , 2018, 132, 487-487.	0.6	41
7	Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Efficacy of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). <i>Blood</i> , 2017, 130, 89-89.	0.6	41
8	Discussing investigational AAV gene therapy with hemophilia patients: A guide. <i>Blood Reviews</i> , 2021, 47, 100759.	2.8	40
9	Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. <i>Haemophilia</i> , 2019, 25, 668-675.	1.0	38
10	<scp>2021</scp> clinical trials update: Innovations in hemophilia therapy. <i>American Journal of Hematology</i> , 2021, 96, 128-144.	2.0	37
11	The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2016, 35, 147-152.	1.6	28
12	Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. <i>Journal of Pediatrics</i> , 2021, 228, 252-259.e1.	0.9	23
13	Shifting landscape of hemophilia therapy: Implications for current clinical laboratory coagulation assays. <i>American Journal of Hematology</i> , 2018, 93, 1082-1090.	2.0	19
14	The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. <i>American Journal of Hematology</i> , 2020, 95, 960-965.	2.0	19
15	Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. <i>Haemophilia</i> , 2020, 26, e128-e129.	1.0	19
16	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	1.6	18
17	Transition considerations for extended half-life factor products. <i>Haemophilia</i> , 2015, 21, 285-288.	1.0	17
18	Recombinant porcine factor <scp>VIII</scp> for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. <i>Haemophilia</i> , 2017, 23, e93-e98.	1.0	17

#	ARTICLE	IF	CITATIONS
19	The spectrum of bleeding in women and girls with haemophilia B. <i>Haemophilia</i> , 2018, 24, 180-185.	1.0	15
20	Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. <i>Blood Advances</i> , 2019, 3, 4166-4176.	2.5	15
21	An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 880-890.	1.7	14
22	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 607-614.	1.0	13
23	Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 326-333.	1.0	13
24	Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 316-326.	0.5	13
25	A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. <i>Pediatric Critical Care Medicine</i> , 2022, 23, e1-e9.	0.2	12
26	The "Natural study" The outcome of immune tolerance induction therapy in patients with severe haemophilia B. <i>Haemophilia</i> , 2021, 27, 802-813.	1.0	11
27	Kaposiform Lymphangiomatosis. <i>American Journal of Surgical Pathology</i> , 2022, 46, 963-976.	2.1	11
28	Novel dominant β -thalassemia: Hb Boston-Kuwait [Codon 139/140(+T)]. <i>Pediatric Blood and Cancer</i> , 2013, 60, E131-4.	0.8	10
29	Evolving Complexity in Hemophilia Management. <i>Pediatric Clinics of North America</i> , 2018, 65, 407-425.	0.9	10
30	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1822-1828.	0.8	8
31	Clinical application of Web Accessible Population Pharmacokinetic Service "Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. <i>Haemophilia</i> , 2020, 26, 56-63.	1.0	7
32	Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. <i>Pediatric Blood and Cancer</i> , 2016, 63, 499-503.	0.8	6
33	Natural history study of factor IX deficiency with focus on treatment and complications ("Natural"). <i>Haemophilia</i> , 2021, 27, 49-59.	1.0	6
34	Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers. <i>Blood</i> , 2019, 134, 2407-2407.	0.6	6
35	Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 133-137.	1.9	6
36	Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28004.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€“ Unmet needs remain. Haemophilia, 2022, 28, 453-461.	1.0	5
38	Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 449-460.	0.5	5
39	Phage display broadly identifies inhibitorâ€reactive regions in von Willebrand factor. Journal of Thrombosis and Haemostasis, 2021, 19, 2702-2709.	1.9	4
40	First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Î. Blood, 2020, 136, 8-8.	0.6	4
41	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
42	Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. Journal of Thrombosis and Haemostasis, 2021, 19, 976-982.	1.9	3
43	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€Oâ€HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia, 2020, 26, 3-19.	1.0	3
44	Author's response: â€Transition considerations for extended half-life factor productsâ€™. Haemophilia, 2015, 21, e454-e455.	1.0	2
45	Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centreâ€based pharmacy hit the mark?. Haemophilia, 2015, 21, 190-195.	1.0	2
46	Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. Pediatric Blood and Cancer, 2020, 67, e28497.	0.8	2
47	Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. Haemophilia, 2021, 27, e270-e273.	1.0	2
48	Diagnostic and Therapeutic Decision Making in Pediatric Patients with Low Von Willebrand Factor. Blood, 2019, 134, 2414-2414.	0.6	2
49	Resolving bony abnormality evolves to diffuse large Bâ€cell lymphoma. Pediatric Blood and Cancer, 2013, 60, E113-5.	0.8	1
50	Thrombotic Events with NovoSevenÂ® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs. Blood, 2018, 132, 1203-1203.	0.6	1
51	Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. Blood, 2019, 134, 3637-3637.	0.6	1
52	Incidence of Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium. Blood, 2020, 136, 5-6.	0.6	1
53	Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia, 2019, 25, e126-e129.	1.0	0
54	Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients.. Journal of Clinical Oncology, 2014, 32, 222-222.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates. <i>Blood</i> , 2018, 132, 2467-2467.	0.6	0
56	The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning. <i>Blood</i> , 2019, 134, 635-635.	0.6	0
57	Assessing Venous Thromboembolism Risk in Critically Ill Children: A Report from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium. <i>Blood</i> , 2019, 134, 1150-1150.	0.6	0
58	Assessment of TRM-201 (Rofecoxib) Efficacy and Safety for Chronic Pain in Hemophilic Arthropathy: The Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA), a Randomized, Double-Blind Placebo-Controlled Phase III Clinical Trial. <i>Blood</i> , 2021, 138, 4243-4243.	0.6	0
59	Assessing Patient and Provider Perspectives, Clinical Practice, Behaviors, and Knowledge on Hemophilia A Care. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
60	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
61	Hemophilia A/B. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 797-812.	0.9	0